UNDERWRITING AGREEMENTUnderwriting Agreement • October 4th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • New York
XORTX Therapeutics Inc., a company organized under the laws of British Columbia (the “Company”), proposes to issue and sell, severally and not jointly, to A.G.P./Alliance Global Partners (the “Representative”) and the other underwriters named on Schedule I hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) (i) an aggregate of [__] common share units (the “Common Share Units”), with each Common Share Unit consisting of (A) one common share (each a “Firm Share” and collectively the “Firm Shares”), no par value per share, of the Company (the “Shares”), and (B) a warrant to purchase [__] Shares (each a “Firm Warrant” and collectively the “Firm Warrants”) and (ii) an aggregate of [ ] pre-funded warrant units (the “Pre-Funded Warrant Units”), with each Pre-Funded Warrant Unit consisting of (A) a pre-funded warrant to purchase [__] Shares at an exercise
